Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe nasal polyposis.


Clinical Trial Description

Approximately 275 patients will be randomized to receive benralizumab 30 mg SC or matching placebo. After enrolment, eligible patients will enter a 6-week screening/run in period. Patients who meet eligibility criteria will be randomised 1:1 at Week 0 (Day 0) to receive either placebo or benralizumab 30 mg SC every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48). An end of treatment visit will be conducted at Week 56.All patients who complete the 56-week DB treatment period on investigational product (IP) may be eligible to continue into around one year OLE, during which all patients will receive 8 doses of benralizumab 30 mg. Patients in Benra arm during DB period will receive one dummy dose. The last study visit will occur at 8 weeks after the last dose of IP (Week 112/FU). Patients who do not enter OLE, will have their last study visit at Week 56 (EoDB) for follow-up and without administration of IP. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04157335
Study type Interventional
Source AstraZeneca
Contact
Status Active, not recruiting
Phase Phase 3
Start date November 25, 2019
Completion date October 10, 2025

See also
  Status Clinical Trial Phase
Completed NCT04532736 - Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis Phase 2
Completed NCT02784262 - Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis Phase 2
Completed NCT02562924 - The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery N/A
Completed NCT00480298 - Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis Phase 2
Completed NCT03358329 - Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE) Phase 3
Active, not recruiting NCT01906697 - The Effect of RF Turbinoplasty in Polypoid Change of Middle Turbinates Phase 3
Completed NCT03591068 - Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video Phase 3
Recruiting NCT05056714 - Development of a Severity Assessment Score for Nasosinus Polyposis (PSI Score)
Completed NCT03401229 - Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis Phase 3
Recruiting NCT03979716 - Smell Exploration in Patients With Nasal Polyposis : Study by Functional Magnetic Resonance Imaging N/A
Not yet recruiting NCT05131958 - Nasality Evolution in a Nasal Polyposis Context : Multiparametric Evaluation : Articulatory (Imaging), Aerodynamics, Acoustics and Perception
Completed NCT02291549 - S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps Phase 3
Completed NCT01393340 - Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma Phase 2
Completed NCT02734849 - Study to Evaluate Multiple Doses in Patients With Nasal Polyposis Phase 2